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Abstract
Background: Although distress screening is crucial for cancer survivors, it is not easy for clinicians to recognize distress.
Physical activity (PA) data collected by mobile devices such as smart bands and smartphone apps have the potential to be used
to screen distress in breast cancer survivors.
Objective: The aim of this study was to assess data collection rates of smartphone apps and smart bands in terms of PA data,
investigate the correlation between PA data from mobile devices and distress-related questionnaires from smartphone apps, and
demonstrate factors associated with data collection with smart bands and smartphone apps in breast cancer survivors.
Methods: In this prospective observational study, patients who underwent surgery for breast cancer at Asan Medical Center,
Seoul, Republic of Korea, between June 2017 and March 2018 were enrolled and asked to use both a smartphone app and smart
band for 6 months. The overall compliance rates of the daily PA data collection via the smartphone walking apps and wearable
smart bands were analyzed in a within-subject manner. The longitudinal daily collection rates were calculated to examine the
dropout pattern. We also performed multivariate linear regression analysis to examine factors associated with compliance with
daily collection. Finally, we tested the correlation between the count of daily average steps and distress level using Pearson
correlation analysis.
Results: A total of 160 female patients who underwent breast cancer surgeries were enrolled. The overall compliance rates for
using a smartphone app and smart bands were 88.0% (24,224/27,513) and 52.5% (14,431/27,513), respectively. The longitudinal
compliance rate for smartphone apps was 77.8% at day 180, while the longitudinal compliance rate for smart bands rapidly
decreased over time, reaching 17.5% at day 180. Subjects who were young, with other comorbidities, or receiving antihormonal
therapy or targeted therapy showed significantly higher compliance rates to the smartphone app. However, no factor was associated
with the compliance rate to the smart band. In terms of the correlation between the count of daily steps and distress level, step
counts collected via smart band showed a significant correlation with distress level.
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Conclusions: Smartphone apps or smart bands are feasible tools to collect data on the physical activity of breast cancer survivors.
PA data from mobile devices are correlated with participants’ distress data, which suggests the potential role of mobile devices
in the management of distress in breast cancer survivors.
Trial Registration: ClinicalTrials.gov NCT03072966; https://clinicaltrials.gov/ct2/show/NCT03072966
(J Med Internet Res 2019;21(9):e13463)  doi: 10.2196/13463
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Introduction
Distress screening is important in cancer survivorship care. The
prevalence of depression and anxiety were reported to be high
among cancer survivors [1,2]. The National Comprehensive
Cancer Network and American Society of Clinical Oncology
guidelines recommend all cancer patients be screened for
depressive symptoms [3,4].
Although distress screening is crucial for cancer survivors, it is
not easy for clinicians to recognize distress. Some studies have
demonstrated that the prevalence and severity of depression are
underestimated [4,5]. Moreover, conventional screening tools
for distress are patient-reported outcomes (PROs) based on
paper questionnaires, which are subject to recall bias and do
not reflect real-time episodes of distress.
Electronic PROs (ePROs) using a smartphone app can be used
as a screening tool for depression in practice [6]. While the
completion rate of online questionnaires in cancer patients was
about 15.0% from home, the overall compliance rate increased
when patients used smartphone apps [7-9]. Although ePROs
using apps is a feasible tool for distress screening, there is still
room for improvement in adherence rates.
Researchers have recently suggested that changes in physical
activities (PA) per the data collected by wearable devices can
predict mood changes [10-11]. PA data collected by mobile
devices such as smart bands and smartphone apps to screen
distress in cancer survivors could offer tremendous advantages.
However, the previous studies were not conducted in cancer
survivors, the sample size was relatively small, and distress or
depression was not evaluated by conventional screening tools.
The prerequisite and essential condition for using mobile devices
for data collection is compliance to mobile devices. However,
long-term compliance to mobile devices, especially in clinical
setting, has rarely been studied. According to a systematic
review [12], among compliance studies with mobile
device–based ecological momentary assessment, about half of
the studies (24/42, 62%) recruited youth from nonclinical
settings, the length of studies ranged only from 2 to 42 days,
and the sample size in clinical settings was small (range 5 to 84
participants). Until now, there has been a lack of evidence about
long-term compliance and data collection using mobile devices.
We conducted a single-center, prospective, observational study
with 160 breast cancer patients who underwent breast cancer
surgery and 6-month follow-up. The aim of this study was to
assess data collection rates of smartphone apps and smart bands
in terms of PA data to investigate the correlation between PA
data from mobile devices and distress-related questionnaire data
from smartphone apps and demonstrate factors associated with
data collection with smart bands and smartphone apps in breast
cancer survivors.
Methods
Study Setting and Subjects
This prospective observational study recruited patients who
underwent surgeries for breast cancer at Asan Medical Center,
Seoul, Republic of Korea. Patients were eligible for study
participation if they were women between the ages of 20 and
65 years and had their own Android smartphones compatible
with the WalkOn app (Swallaby Co, Ltd), a free activity tracking
app modified for this study. Patients who had distant metastasis,
recurrent breast cancer, or severe medical conditions such as
cardiovascular disease and those who had no capability of using
a smartphone were excluded. Patients on chemotherapy were
also excluded.
Written informed consent was obtained from all subjects at
enrollment. The study protocol was approved by the institutional
review board at Asan Medical Center (2016-0819). This study
was registered on the ClinicalTrial.gov website (NCT03072966).
Recruitment and Follow-Up
During the hospital stay after breast cancer surgery, subjects
were contacted by a clinical research assistant. After consenting
to participate, subjects completed paper-based questionnaires
(Distress Thermometer [DT] and Patient Health Questionnaire–9
[PHQ-9]) at baseline. The clinical research assistant helped to
download the Android-based app (WalkOn) to the participants’
smartphones.
At the first visit to the clinic after discharge, subjects who are
not undergoing adjuvant chemotherapy received wearable
devices (Fitbit Charge HR, Fitbit Inc), and the Fitbit apps were
installed on their smartphones. Subjects scheduled to receive
adjuvant chemotherapy were provided the wearable devices
after chemotherapy. The clinical research assistant called
participants after 3 weeks to follow up and assist with collection
of data from the wearable devices. At the 3- and 6-month
follow-ups, participants’ smartphone apps and smart bands were
checked by the clinical research assistant.
Smartphone App and App-Based Questionnaire
The health-related smartphone app, WalkOn, has been developed
by the mobile phone health care app company, Swallaby Co,
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Ltd. The app provides users with platforms for tracking their
daily steps and creates mobile communities where users can
communicate with each other and view other members’ daily
steps to motivate them and promote health-related activities.
App-based self-reporting questionnaires have been included in
this app, which exclusively allows study participants to complete
daily, weekly, and biweekly questionnaires. The daily
questionnaires developed and previously reported by the authors
consisted of self-reporting modules for daily anxiety, sleep, and
emotion [6,9]. Weekly DT and biweekly PHQ-9 questionnaires
were also collected through the app, and push alarms from
Sunday to Tuesday every week were sent to subjects’
smartphones as notification.
Activity Tracking From Smartphone Apps and Smart
Bands
We used the app to collect data on participants’ daily steps.
Once the app was activated at enrollment, participants were
instructed to open the app and pull-to-refresh the front page of
the app at least once weekly to send the weekly bundle of daily
walking data to a central database system. The central database
system collected the daily walking data for each subject with
anonymized user ID, item ID, date and time of input, and input
value.
As a second channel for data collection, a smart band (Fitbit
Charge HR) was also used to monitor daily PA and sleep
patterns in real time during the 6-month study period. Briefly,
the Fitbit Charge HR is designed to measure various PAs such
as steps taken, distance traveled, and calories burned. It also
shows users how many minutes they have been active during
the day. Similar to the walking app, after Fitbit activation,
participants were instructed to access the Fitbit app and
pull-to-refresh at least once per week to send the weekly set of
daily walking data to the server. The Fitbit app also sent a push
notification to the users about changes in daily activity patterns.
While the mobile walking app only collects the number of steps
per day, the Fitbit collects various indicators about PA each
minute. The central database system collected all indicators at
both minute- and day-levels using anonymized user ID, item
ID, date and time of input, and input values.
Statistical Analysis
The feasibility of the app-based and smart band–based PA
collecting systems were analyzed by calculating individual-level
data collection rates, defined as the total number of days in
which data collection was completed divided by the number of
follow-up days for each patient as well as a longitudinal
day-level data collection rate, defined as the total number of
patients with PA data divided by the number of patients who
did not drop out on a single specific day from the start of data
collection. The cumulative longitudinal day-level data collection
rate was defined as the mean of all longitudinal day-level data
collection rates from the starting day until the specified day.
For example, the longitudinal day-level collection rate at day
20 indicated the number of patient data collection points on the
20th day divided by 160, while the cumulative longitudinal
day-level data collection rate at 20th day was the mean value
of all longitudinal day-level data collection rates from day 0 to
day 20. The definitions of individual-level, longitudinal
day-level, and cumulative longitudinal day-level data collection
rates were similar with the measurements of compliance which
were described previously [9].
Student t tests and chi-square tests were used to investigate the
differences in patient characteristics between high and low data
collection rate groups. The variables of interest included age,
marital status, education, occupation, comorbidity, past episode
of depression, surgery, chemotherapy, radiation therapy,
antihormonal therapy, targeted therapy, and stage. The mean
value of individual-level data collection rates was used as the
cutoff to divide the high and low collection rate groups. The
mean individual-level rates were 91.1% for the smartphone app
and 55.0% for the smart band.
The Pearson correlation test was used to calculate the correlation
between app-based and band-based collection rates. To more
comprehensively investigate the factors affecting
individual-level collection rates, we conducted multivariate
linear regression analysis for both app- and band-based data
collection rates with all variables. Since two patients did not
report baseline distress levels in presurvey, we exclude them
from step 2 and 3 analyses.
Finally, we examined the correlation between app-based and
band-based step counts and distress-related psychological
questionnaires using Pearson correlation tests.
Results
Descriptive Statistics
From June 2017 to January 2018, we assessed for study
eligibility 1247 consecutive patients who underwent breast
cancer surgery (Figure 1). After screening, 591 patients were
excluded; 176 patients were not able to be contacted during the
hospital stay and 320 patients refused to join the study. A total
of 160 patients were enrolled in this study. During follow-up,
33 participants withdrew consent due to inconvenience (n=26),
transfer to other hospitals (n=2), app compatibility problems
after update (n=4), and breast cancer recurrence (n=1).
Table 1 summarizes descriptive statistics of the demographic
and clinical characteristics of the subjects as absolute and
relative frequencies. Subjects were aged mean 45.3 [SD 6.8]
years (range 28 to 64 years), and about three-quarters (121/160,
75.6%) were younger than 50 years. Sixty-four subjects
completed adjuvant or neoadjuvant chemotherapy before
beginning daily data collection. Among the 160 patients, 75.6%
(121/160) were less than 50 years of age, 66.9% (107/160) had
an educational attainment of college level or higher, and 47.5%
(76/160) were currently employed. The mean baseline EQ5D-5L
score was 0.91 (SD 0.1). Regarding breast cancer stages, 13.1%
(21/160) of patients had stage 0, 48.1% (77/160) had stage I,
24.4% (39/160) had stage II, and 14.4% (23/160) had stage III
disease.
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Figure 1. Subject enrollment.
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Table 1. Subject demographics.
Band complianceApp complianceTotal (N=160)Characteristics
P valueLower (n=80)Higher (n=80)P valueLower (n=27)Higher (n=133)
.4345.7 (7.1)44.9 (6.5).1347.1 (6.4)44.9 (6.9)45.3 (6.8)Age (years), mean (SD)
.1456 (70.0)65 (81.3).3518 (66.7)103 (77.4)121 (75.6)<50, n (%)
—24 (30.0)15 (18.7)
—
a9 (33.3)30 (22.6)39 (24.4)≥50, n (%)
.73.63Marital status, n (%)
67 (83.8)70 (87.5)23 (85.2)114 (85.7)137 (85.6)Married
11 (13.7)9 (11.3)3 (11.1)17 (12.8)20 (12.5)Single
2 (2.5)1 (1.2)1 (3.7)2 (1.5)3 (1.9)Other
.74.49Education, n (%)
28 (35.0)25 (31.3)11 (40.7)42 (31.6)53 (33.1)≤High school
52 (65.0)55 (68.7)16 (59.3)91 (68.4)107 (66.9)>High school
.43.33Occupation, n (%)
35 (43.8)41 (51.3)10 (37.0)66 (49.6)76 (47.5)Yes
45 (56.2)39 (48.8)17 (63.0)67 (50.4)84 (52.5)No
.24.03Comorbidity, n (%)
58 (72.5)50 (62.5)13 (48.1)95 (71.4)108 (67.5)Yes
22 (27.5)30 (37.5)14 (51.9)38 (28.6)52 (32.5)No
.84.498Past episode of depression, n (%)
1 (1.3)1 (1.3)0 (0)2 (1.5)2 (1.3)Yes
75 (93.7)77 (96.3)25 (92.6)127 (95.5)152 (95.0)No
4 (5.0)2 (2.4)2 (7.4)4 (3.0)6 (3.8)No response
.08.60Surgery, n (%)
4 (5.0)7 (8.8)2 (59.3)9 (6.8)11 (6.9)Mastectomy
49 (61.3)58 (72.5)16 (7.4)91 (68.4)107 (66.9)Breast-conserving surgery
27 (33.7)15 (18.8)9 (33.3)33 (24.8)42 (26.3)Mastectomy with reconstruction
.33.28Previous chemotherapy, n (%)
29 (36.3)36 (45.0)14 (51.9)51 (38.3)65 (40.6)Yes
51 (63.7)44 (55.0)13 (48.1)82 (61.7)95 (59.4)No
>.99.04Antihormonal therapy, n (%)
67 (83.7)68 (85.0)19 (70.4)116 (87.2)135 (84.4)Yes
13 (16.3)12 (15.0)8 (29.6)17 (12.8)25 (15.6)No
.34.47Radiation therapy, n (%)
59 (73.8)65 (81.3)19 (70.4)105 (78.9)124 (77.5)Yes
21 (26.3)15 (18.7)8 (29.6)28 (21.1)36 (22.5)No
.76.01Targeted therapy, n (%)
75 (93.8)73 (91.3)21 (77.8)127 (95.5)148 (92.5)Yes
5 (6.2)7 (8.7)6 (22.2)6 (4.5)12 (7.5)No
.42.31Stage, n (%)
13 (16.3)8 (10.0)5 (18.5)16 (12.0)21 (13.1)0
38 (47.5)39 (48.8)9 (33.3)68 (51.1)77 (48.1)I
16 (20.0)23 (28.7)9 (33.3)30 (22.6)39 (24.4)II
13 (16.3)10 (12.5)4 (14.8)19 (14.3)23 (14.4)III
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Band complianceApp complianceTotal (N=160)Characteristics
P valueLower (n=80)Higher (n=80)P valueLower (n=27)Higher (n=133)
.32.29Distress thermometer score, n (%)
33 (41.3)26 (32.5)13 (48.1)46 (34.6)59 (36.9)≥5
46 (57.5)53 (66.3)14 (51.9)85 (63.9)99 (61.9)≤5
1 (1.2)1 (1.2)0 (0)2 (1.5)2 (1.2)No response
.44.14HRQOLb with EQ5D-5Lc
0.90 (0.1)0.92 (0.1)0.87 (0.1)0.92 (0.1)0.91 (0.1)EQ5D-5L index, mean (SD)
1 (1.2)1 (1.2)0 (0)2 (1.5)2 (1.2)No response, n (%)
.71.93PHQ-9d total score, n (%)
17 (21.3)20 (25.0)7 (25.9)30 (22.6)37 (23.2)≥11
62 (77.5)59 (73.8)20 (74.1)101 (75.9)121 (75.6)≤11
1 (1.2)1 (1.2)0 (0)2 (1.5)2 (1.2)No response
.18168 (30.2)160 (46.6).95164 (40.4)164 (39.3)164 (39.3)Median follow-up in days, median (SD)
aNot applicable.
bHRQOL: Health-Related Quality of Life.
cEQ5D-5L: 5-dimension 5-level health questionnaire.
dPHQ-9: Patient Health Questionnaire–9.
Data Collection Rates
Among 160 participants, 127 completed the 180-day study
period, and 33 patients had different follow-up periods
depending on the withdrawal date (minimum: 11 days,
maximum: 176 days, median: 101 days). The total sum of
follow-up days of all participants is 27,513, slightly less than
28,800 (160*180) because of patient dropout.
In total, 24,224 and 14,431 data points were collected via
smartphone apps and smart bands, respectively. The overall
data collection rates for using the smartphone app and smart
band were 88.05% (24,224/27,513) and 52.45% (14,431/27,513),
respectively.
The data collection rate via smartphone app was >80% for 141
subjects (88.1%) and via smart band was >80% for 53
participants (33.1%). The longitudinal day-level data collection
rates from day 1 to day 180 were calculated at daily intervals
and plotted (Figure 2). For the smartphone app, the longitudinal
data collection rate remained above 75%, reaching 77.8% at
day 180, while the cumulative longitudinal data collection curve
showed a steady decrease to 88% (representing overall data
collection) at day 180. Although cumulative longitudinal data
collection with smart bands was 46% at day 90, longitudinal
compliance rate for smart bands more rapidly decreased,
reaching 17.5% at day 180.
Daily data collection of mobile questionnaires is relatively
smaller than the daily data collection of the semiautomated
walking steps collection systems. The daily questionnaires
consisted of self-reporting modules for daily anxiety, sleep, and
emotion questionnaire [6,9], and in total, 20,733 data points
were collected via the smartphone app. The overall data
collection rate for using the smartphone app self-reporting
modules was 75.36% (20,733/27,513). Therefore, we can use
the self-reported value of daily anxiety, sleep, and emotion as
focal outcome variables to develop distress screening system
in our future study. The weekly DT and biweekly PHQ-9 were
also collected through the same app, and the overall weekly
data collection rates for them were 42.42% (3597/8480) and
41.86% (1775/4240), respectively. As we expected, the
self-reported value was less diligently collected than the
semiautomated walking step counts.
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Figure 2. Longitudinal day-level data collection rates: (A) smartphone app; (B) smart band.
Factors Related to Data Collection Rates
In univariate analyses, comorbidities, antihormonal therapy,
and targeted therapy were significantly associated with greater
data collection rates with the walking app (Table 1). Table 2
shows the results of hierarchical regression analysis. In the first
step including demographic variables, no factors were associated
with data collection rates for smartphone apps and smart bands.
In step 2, we added clinical factors to the model. Since clinical
factors such as the types of therapy patients received are
important to explain the data collection rate, the amount of
variance explained by data collection rates with the app
increased to 11.7%, with age, comorbidity, antihormonal
therapy, and targeted therapy as significant predictors. Age
became a significant factor in step 2 as other factors were
included in the model. In step 3, the final model explained 12%
of the variance in the data collection rates with the smartphone
app. All variables with significance in step 2 remained
significant in the final model. Young women were more
compliant in the collection of PA data via the smartphone app.
Subjects with any kind of disease in addition to breast cancer
had a higher rate of data collection with the app (P=.001; Table
2). Patients on antihormonal (P=.009) or targeted (P=.011)
therapies had significantly higher rates of data collection with
the app (Table 2). In contrast, no demographics or clinical
factors were associated with compliance with wearing the smart
band (Table 3).
We also tested the correlation between the data collection rates
for the use of the app and smart band. The 95% confidence
interval ranged from –0.22 to 0.09, and the P value was 0.41,
indicating there was no correlation between these data collection
rates.
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Table 2. Factors associated with data collection with the smartphone app in multivariate analysis.
Step 3: depression-related
factors (n=158)
Step 2: clinical factors
(n=158)
Step 1: demographics
(N=160)
Variable
P valueBetaP valueBetaP valueBeta
.0030.90.0060.71<.0011.09Constant
.02–0.01.04–0.01.22–0.01Age
.14–0.09.10–0.01.15–0.09Marital status: single
.700.06.410.11.810.03Marital status: other
.62–0.02.68–0.02.97–0.01≤High school
.94–0.01.930.01.95–0.01No occupation
.0010.13.0020.13—
—
aComorbidity: yes
.20–0.12.25–0.11——Mastectomy (baseline: breast-conserving surgery)
.26–0.08.10–0.11——Mastectomy with reconstruction (baseline: breast-conserving
surgery)
.490.04.450.04——Previous chemotherapy
.0090.14.010.14——Antihormonal therapy
.33–0.07.25–0.08——Radiation therapy
.010.20.020.17——Targeted therapy
.900.01.620.03——Stage I (baseline: stage 0)
.39–0.06.58–0.04——Stage II
.300.09.250.10——Stage III
.140.31.270.22——EQ5D-5Lb index
.13–0.07————Distress Thermometer ≥5
.490.04————PHQ-9c ≥11
.17–0.24————Previous depression: no
.39–0.18————Previous depression: no response
.0080.12.0050.12.68–0.01Adjusted R2
aNot applicable.
bEQ5D-5L: 5-dimension 5-level health questionnaire.
cPHQ-9: Patient Health Questionnaire–9.
J Med Internet Res 2019 | vol. 21 | iss. 9 | e13463 | p. 8https://www.jmir.org/2019/9/e13463
(page number not for citation purposes)
Chung et alJOURNAL OF MEDICAL INTERNET RESEARCH
XSL•FO
RenderX
Table 3. Factors associated with data collection with smart bands in multivariate analysis.
Step 3: depression-related
factors (n=158)
Step 2: clinical factors
(n=158)
Step 1: demographics
(N=160)
Variable
P valueBetaP valueBetaP valueBeta
.090.81.020.94.0020.65Constant
.58–0.01.62–0.00.81–0.01Age
.63–0.05.47–0.07.53–0.06Marital status: single
.49–0.18.498–0.15.71–0.08Marital status: other
.91–0.01.98–0.01.88–0.01≤High school
.28–0.07.26–0.07.26–0.07No occupation
.67–0.03.66–0.03—
—
aComorbidity: yes
.170.21.190.20——Mastectomy (baseline: breast-conserving surgery)
.27–0.12.17–0.15——Mastectomy with reconstruction (baseline: breast-conserving
surgery)
.460.07.460.06——Previous chemotherapy
.83–0.02.70–0.03——Antihormonal therapy
.680.05.670.05——Radiation therapy
.68–0.05.56–0.07——Targeted therapy
.190.12.140.14——Stage I (baseline: stage 0)
.220.1.190.15——Stage II
.92–0.01>.990.01——Stage III
.53–0.21.36–0.29——EQ5D-5Lb index
.29–0.07————Distress Thermometer ≥5
.170.11————PHQ-9c ≥11
.840.06————Previous depression: no
.970.01————Previous depression: no response
.60–0.01.51–0.01.87–0.02Adjusted R2
aNot applicable.
bEQ5D-5L: 5-dimension 5-level health questionnaire.
cPHQ-9: Patient Health Questionnaire–9.
Correlation Between Physical Activity and Patient
Distress
In Pearson correlation tests, for smart bands, anxiety, emotion,
DT, and the sum of PHQ-9 were negatively correlated with the
daily average steps (Table 4). Since these psychological factors
were asked to be scored high when the patients felt more
depressive, the negative correlation means more daily steps
relates with lower distress. The sleep disturbance answer was
positively correlated with the daily average steps. Since the
sleep disturbance score was asked to be scored low when
patients felt unable to sleep, the positive correlation means
higher daily steps relates with higher quality of sleep. For the
smartphone app, all psychological domains show the same
direction of correlation with the daily average steps as for the
smart band, although the coefficients were not statistically
significant for all domains.
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Table 4. Correlation between daily steps and examined psychological domains.
Smart bandSmartphone appPsychological domains
P valueCoefficientP valueCoefficient
.008–0.23.38–0.07Anxiety (0-10)
.003–0.24.71–0.03Emotion (0-10)
.020.20.360.08Sleep (0-10)
<.001–0.31.11–0.13Distress Thermometer (0-10)
<.001–0.30.15–0.12Patient Health Questionnaire–9 sum (0-27)
Discussion
Principal Findings
Our results indicate that both smartphone app– and smart
band–based technologies are feasible tools to collect PA data
from breast cancer survivors. The overall data collection rates
using both smartphone walking apps and smart bands were
higher than the self-reporting rates with smartphone apps in our
previous study, despite the longer follow-up period in this study
[9]. Although data collection rates with smart bands rapidly
decreased over time, PA data from smart bands were
significantly correlated with participants’ distress data. Patients
who were young, with comorbidities, or receiving antihormonal
or targeted therapies were more likely to be adherent to
smartphone apps.
To our knowledge, this is the one of the largest prospective
studies to assess PA data collection using mobile devices with
a longer term of follow-up. In addition, the unique feature of
this study is that we enrolled breast cancer patients who are
usually recommended to be screened for depressive symptoms,
and their depressive symptoms were significantly correlated
with PA data from their mobile devices in our study. These
results suggest that mobile devices have a significant potential
as tools for distress screening in these patients with unmet needs.
Two types of PA data can be collected via smartphone apps.
First, self-reported data manually capture health information.
For the self-reporting of PA, PA app users self-monitored and
recorded exercise more frequently over a 6-month study (2.6
[SD 0.5] days per week) than did non-app users (1.2 [SD 0.5]
days per week PA self-monitoring, P=.001) [13]. This finding
suggested that app-based PA self-reporting is better than
non-app–based methods such as paper or Web questionnaires;
however, the overall compliance was only 37%. Second, PA
data may be obtained from mobile phone sensing via built-in
or external sensors. There are a few feasibility studies on the
daily collection of PA data through mobile apps or smart bands.
One study reported that the number of days with nontypical
wear patterns of wearable devices (Fitbit One) ranged from 5%
to 9% of all observation points for 5 weeks [14]. Days were
marked as nontypical to indicate that the tracker may not have
been consistently worn throughout the day and/or data were not
recorded, possibly due to a depleted battery. Although the
number of missing days was small, the follow-up period was
too short. Longer follow-up periods can result in lower
compliance rates. Therefore, feasibility studies of daily
collection rate of PA through smart bands should be conducted
with longer follow-up periods. Our study investigated this issue
with more subjects during a longer follow-up period. The results
showed that the data collection rates with the smartphone app
and smart bands remained higher for 6 months compared with
those in other studies.
In terms of cancer survivors, previous studies focused on ePRO
data, questionnaires collected via a downloadable app or
Web-based portal [15,16]. Authors from a German cancer center
reported an adherence rate to a smartphone app–based
questionnaire of about 70% in 40 cancer patients over about
100 days [17]. Our previous studies demonstrated an overall
compliance rate to an app-based questionnaire of 45% in 30
participants over a 90-day study period [9]. The overall data
collection rates with mobile devices in our study were higher
than the self-reporting rates in smartphone apps in previous
studies.
We found that female breast cancer patients who were young,
with comorbidities, or receiving antihormonal or targeted
therapies tended to be more adherent to the use of smartphone
apps. After enrollment, some patients were administered
antihormonal or targeted therapies according to clinical practice
guidelines. In terms of antihormonal therapy, patients generally
have to take medications daily for 5 to 10 years [18]. Patients
administered targeted therapy are usually required to visit the
hospital every 3 weeks for approximately 1 year [19]. Patients
with other comorbidities may also have to take other medicines
or visit the clinic regularly. Thus, one possible explanation is
that patients with a regular lifestyle such as taking medicines
every day are more likely to check their time schedule with their
smartphone, which may lead to increased adherence to
smartphone apps. Breast cancer patients are more actively
involved in PA collection through smartphone apps because
wearing smart bands has caused discomfort to the elderly
women. In interviews with patients, we were told that wearing
smart bands was inconvenient, and thus, the patients were more
active in PA collection through apps than bands.
With early diagnosis and improved treatment, the number of
cancer survivors has increased worldwide [20]. Along with the
increased cancer survival rates, more attention should be paid
to the lives of cancer survivors. Recently, digital footprints, data
generated passively through mobile technologies, have been
introduced as tools for psychiatric research [10]. Several studies
have suggested the potential for the use of data from mobile
devices for new measures of mental health [21]. We believe
this study can provide future direction to develop distress
J Med Internet Res 2019 | vol. 21 | iss. 9 | e13463 | p. 10https://www.jmir.org/2019/9/e13463
(page number not for citation purposes)
Chung et alJOURNAL OF MEDICAL INTERNET RESEARCH
XSL•FO
RenderX
screening tool using mobile device–based PA data in breast
cancer survivors.
Limitations
Several limitations of this study should be noted. First, long-term
adherence to wearable devices has not yet been demonstrated.
The follow-up period of this study was 6 months. Second, all
subjects in this study were breast cancer patients. Thus, our
results can only be generalized to this specific population. Third,
all participants were enrolled after the completion of
chemotherapy. Therefore, we do not know the feasibility of
wearable devices to collect PA data during chemotherapy.
Fourth, this study was conducted in a single institution, although
the clinical characteristics of the patients in this study were
similar to those in a nationwide study [22]. Finally, since we
cannot figure out how many hours a day patients were wearing
the band and carrying the app, we could not evaluate data quality
in terms of time span. Future studies should evaluate the time
span of each data collection rather than examining the daily
collection of PA.
Conclusion
Smartphone apps or smart bands are feasible tools to collect
daily PA data in breast cancer survivors. PA data from mobile
devices are correlated with participants’ distress data, which
suggests the potential role of mobile devices in the management
of distress in breast cancer survivors. Further research should
focus on the interpretation and integration of PA data into
clinical practice for the care of breast cancer survivors.
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